BridgeBio Pharma Inc (NAS:BBIO)
$ 27.94 0.18 (0.65%) Market Cap: 5.23 Bil Enterprise Value: 6.44 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 54/100

BridgeBio Pharma Inc Topline Results Transcript

Jul 17, 2023 / 12:00PM GMT
Release Date Price: $32.04 (+75.85%)
Operator

Good day, and thank you for standing by. Welcome to today's discussion with BridgeBio, which will cover the company's topline 30-month results from the Phase III ATTRibute-CM study in patients with transthyretin amyloid cardiomyopathy. (Operator Instructions). Please be advised that today's conference is being recorded.

I would now like to introduce you to the speakers today. Jonathan Fox, MD, PhD, Chief Medical Officer of BridgeBio Cardiorenal; Uma Sinha, PhD, Chief Scientific Officer of BridgeBio; Matt Outten, MBA, ALM CPC, Chief Commercial Officer of BridgeBio.

I will now hand it over to Neil Kumar, CEO of BridgeBio.

Neil Kumar
BridgeBio Pharma, Inc. - Co-Founder, President, CEO & Director

Thank you, operator, and thanks, everyone, for joining this call. I'm grateful to be able to share with you on behalf of the extraordinary physicians, patients, families and caregivers involved the positive Phase III results of our ATTRibute cardiomyopathy clinical trial. The strongly positive and consistent data the community worked tirelessly to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot